France Rejects Merck's COVID-19 Pill: How Bad Is the News?

Submitted by admin on January 2, 2022 - 11:39pm

Source:

Motley Fool

News Tags:

Headline:

snippet:

The French National Authority for Health determined that other therapies were much more effective than molnupiravir.
Merck's agreement with France for the COVID-19 pill was only in the ballpark of $30 million.
Although the French rejection won't hurt Merck much, molnupiravir won't generate the level of sales globally that were anticipated.

Search form